Lab Sciences
Top stories summarized by our editors
12/15/2017

Researchers from Stanford University School of Medicine have been testing a drug candidate that stops flaviviruses such as dengue, Zika and West Nile from replicating in mammalian cells, according to a study in the journal Cell Reports. The drug blocks oligosaccharyltransferase in host cells to deny viruses access to energy through glycan sugar molecules.

12/15/2017

Stemline Therapeutics said a 13-patient trial of lead candidate SL-401 as a treatment for the bone marrow disorder blastic plasmacytoid dendritic cell neoplasm found the drug produced an overall response rate of 77% and a complete response rate of 54%.

12/15/2017

Cyclacel Pharmaceuticals revealed that the primary endpoint was not attained in its late-stage clinical trial to assess the efficacy of its lead candidate sapacitabine among newly diagnosed elderly patients with acute myeloid leukemia, based on a presentation at the American Society of Hematology's annual meeting. The treatment did not provide a statistically significant improvement relevant to overall survival when sapacitabine was combined with decitabine compared with treatment with decitabine alone, but those in the sapacitabine group had a higher rate of complete remission at 17%.

12/14/2017

A chimeric antigen receptor T-cell therapy developed by Novartis for the treatment of diffuse large B-cell lymphoma had a complete response in 30% of 46 participants, while 7% achieved partial responses, according to a presentation at the American Society of Hematology's annual meeting. Novartis anticipates it will have 35 fully operational processing centers for Kymriah by year's end.

Full Story:
Reuters
12/14/2017

Gilead reported that axicabtagene ciloleucel, or Yescarta, was associated with a survival rate of 56% at a median of 15 months in a follow-up study involving 108 patients with aggressive large B-cell lymphoma, according to a presentation at the American Society of Hematology's annual meeting. The remission rate in the follow-up study was 42%.

Full Story:
Reuters
12/14/2017

Akari Therapeutics reported that Coversin, its candidate to treat paroxysmal nocturnal hemoglobinuria, met its primary endpoint during a Phase II trial. Patients achieved a significant reduction in lactate dehydrogenase by the 28th day of treatment.

12/14/2017

A new freeze-dried powder formulation of Oncaspar, or pegaspargase, has received marketing approval from the European Commission. Shire's lyophilized drug, which is administered together with chemotherapy for patients with acute lymphoblastic leukemia, has a longer shelf life and can last for 24 months, compared with its liquid formulation, and will be sold in Europe in the first half of 2018.

12/13/2017

David Oliphant was 47 when he had cardiac arrest and died after a bike race. His family decided to donate his eye and tissue, which gave second chance to more than 50 people, said his sister Beth Oliphant Hoover, who serves as a board member for Donate Life Northwest.

12/13/2017

Hospitals in Pennsylvania and Minnesota were among those honored for their work promoting eye, tissue and organ donation. Olmsted Medical Center's Donate Life Team was recognized by LifeSource for promoting enrollment in state organ donor registries, and Penn Highlands Healthcare was recognized by CORE, the Center for Organ Recovery & Education, and the Gift of Life Donor Program.

12/13/2017

Transfusion-dependent leukemia patients had a 52% shorter hospice stay than patients with leukemia who were not transfusion-dependent and were more likely to have hospice stays of fewer than three days, researchers reported at the American Society of Hematology's annual meeting. Hospice use among leukemia patients has increased over time, and when transfusion-dependent patients received hospice services, their end-of-life quality measures improved.